The short answer: yes, but evidence varies by joint

The short answer is yes. ChondroFiller is CE-marked as a Class III medical device for focal articular cartilage defects without restriction to a single joint — the knee simply has the largest published evidence base.

How confident clinicians can be depends heavily on which joint is being considered. Evidence is most robust for the knee, where several prospective studies spanning 12–36 months have reported consistent functional improvements. For the hip, a meaningful body of cohort data exists, though patient numbers remain smaller. Small joints such as the wrist and thumb carry early-stage clinical findings. For the shoulder, elbow, and temporomandibular joint, peer-reviewed outcome data are largely absent at present.

Across all these joints, the treatment targets a similar defect profile — focal damage rather than widespread joint degeneration — and section six maps out the selection criteria in full. The sections that follow work through each joint in turn, so readers can assess what the published evidence actually says about their specific situation.

Why the scaffold can work in more than one joint

Unlike cell-based cartilage therapies, ChondroFiller carries no living cells of its own. The collagen matrix acts as a chemotactic scaffold: once placed, it draws the body's endogenous progenitor cells — mesenchymal stem cells and local chondrocytes — from the surrounding synovial tissue and subchondral bone. Those cells migrate in, mature, and gradually deposit new cartilage while the collagen matrix is resorbed. Because the repair signal comes from the patient's own biology, the joint type is not, in itself, a biological barrier.

The physical properties reinforce this adaptability. Supplied as a two-component syringe, the liquid collagen self-gels within approximately three to five minutes after placement, conforming precisely to the defect geometry without the need for fibrin glue, pre-shaped implants, or marrow-stimulation drilling. Sub-millimetre cavities and irregularly shaped lesions that would challenge rigid scaffolds can be filled in a single outpatient appointment under ultrasound guidance.

The variables that determine suitability are procedural rather than biological: whether image-guided placement can reach the defect reliably, whether the defect is sufficiently contained, and whether the surrounding subchondral bone is healthy enough to supply migrating progenitor cells. Any synovial joint presenting a focal, contained Grade III or IV lesion with stable alignment and intact subchondral bone is, in principle, a plausible candidate — though plausibility in principle is not the same as clinical proof.

Hip cartilage defects: the strongest non-knee dataset

The hip has more published clinical data behind it than any other non-knee joint — making it the most useful reference point for patients exploring treatment options away from the knee.

A 26-patient prospective cohort (Mazek et al., 2021) followed adults with femoroacetabular impingement and acetabular lesions larger than 2 cm². At three to five years, 17 of 21 evaluable patients had achieved good or excellent results on both MRI and functional scoring. Two patients went on to total hip replacement — a meaningful signal that the treatment does not succeed in every case.

The most practically important finding from that cohort is the failure predictor. Patients with pre-existing Tönnis Grade 2 or 3 osteoarthritis had poor outcomes. This confirms ChondroFiller as a joint-preservation tool: appropriate when meaningful native cartilage and healthy subchondral architecture remain, but not a rescue option for joints already in advanced degeneration.

A 2025 case report (Raju et al.) extends the anatomical reach within the hip. A 32-year-old man with a 15 mm × 5 mm focal lesion on the superoanterior weight-bearing dome of the femoral head achieved complete pain relief and full range of motion without microfracture. It is a single case and should be read as a demonstration of feasibility, not a reliable guide to expected outcomes.

Collectively, the hip evidence is the most substantial available outside the knee — yet it rests on one prospective cohort and a single case report, with no randomised trial and limited patient numbers. Promising, but conclusions require a measured reading of a genuinely thin evidence pyramid.

Wrist and thumb: small-joint applications

Small joints present a practical problem that most scaffold systems cannot solve: the access geometry simply does not accommodate them. ChondroFiller's delivery through fine-gauge (G20–21) cannulas changes that calculation, allowing the injectable collagen to reach sub-millimetre cavities and irregular tears in joints such as the wrist and thumb that would be inaccessible to larger, pre-formed implants.

The wrist evidence comes from a clinical study by Matta et al. examining patients with residual cartilage defects following open reduction and internal fixation of intra-articular distal radius fractures. Published data report significant improvements in NRS pain scores and DASH disability questionnaire results, and post-treatment MRI showed reduction in bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space. These are meaningful signals, though the study represents a single-centre dataset rather than a multicentre trial.

For thumb carpometacarpal arthritis, published series report improvements in both patient-reported pain and disability scores alongside objective functional gains: measurable increases in grip strength and pincer strength on Jamar and pinch testing. Functional improvements of this kind — beyond simple pain reduction — are clinically meaningful in a joint as mechanically demanding as the thumb CMC.

This is early-stage evidence. The cohorts are small, there are no randomised controlled trials, and replication in larger patient groups is needed before firm conclusions can be drawn.

Shoulder, elbow, and TMJ: where evidence is thin

Shoulder, elbow, and temporomandibular joint (TMJ) all appear in manufacturer product documentation and specialist clinical guidance as sites where ChondroFiller has been applied. No peer-reviewed outcome studies for any of these three joints were identified in the published literature.

That absence does not mean the treatment is incompatible with these locations. The underlying biological rationale is not inherently joint-specific, and image-guided placement can access each of these anatomical targets in principle. What is currently absent is clinical confirmation: no prospective cohort, no randomised controlled trial, and no published case series that would allow outcomes for shoulder, elbow, or TMJ to be assessed independently.

One further point for patients who encounter outcome figures in online searches: the 70–85% symptom-relief figure sometimes cited in connection with ChondroFiller appears to pool results across multiple joint types and study populations without stratifying by site. Applying that range to shoulder, elbow, or TMJ applications would be misleading — no specific dataset for those joints currently underpins it.

Anyone exploring ChondroFiller for these applications should seek a specialist assessment and ask directly what clinical evidence the treating clinician is drawing on for that particular joint.

Who is a good candidate regardless of which joint is affected?

The candidate profile that emerges from published data — across knee, hip, wrist, and small-joint cohorts — is notably consistent. Evidence suggests suitable candidates tend to be younger, active adults with focal, contained cartilage damage on a background of otherwise stable joint architecture, without widespread degeneration.

Several factors appear to work against good outcomes regardless of which joint is involved. Widespread degeneration — the equivalent of Tönnis Grade 2–3 osteoarthritis seen in hip cohort data — is a documented predictor of poor results, and the underlying mechanism is not joint-specific: a scaffold relying on endogenous cell recruitment performs poorly in a globally inflamed, degenerate environment rather than a contained focal defect. Uncorrected mechanical malalignment and compromised subchondral bone present the same problem. ChondroFiller fills a defect; it cannot compensate for biomechanical overload or poor bone quality. Patients who have already reached bone-on-bone changes are more likely to need a joint replacement assessment rather than a scaffold approach.

For those who fall outside this profile, that finding is itself useful clinical information — knowing which pathway fits is the purpose of a structured assessment.

Patients exploring this treatment for any joint are best placed to attend a specialist appointment with cross-sectional imaging already to hand — typically MRI — that confirms defect size and containment, establishes OA grade, and gives a clear view of subchondral bone quality. Those three pieces of information are what allow a clinician to advise meaningfully on whether a scaffold injection is appropriate or whether a different pathway is more likely to help.